We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
UK drug discovery and development group Mission Therapeutics has signed a deal with AbbVie focusing on early stage development of specified DUB inhibitors for the